Mirjam H.M. Heemskerk

Has grant

Associate professor, Head of Laboratory of experimental hematology

Leiden University Medical Center

Netherlands

Research Interests

Explore related searches

Professors in Netherlands Professors in Immunology Immunology professors in Netherlands

Contact this professor

ORCID

Google Scholar

About

Mirjam H.M. Heemskerk is an Associate Professor and Head of the Laboratory of Experimental Hematology at Leiden University Medical Center in the Netherlands. Her research focuses on advanced topics in immunology and hematology, including the pathogenesis of immune-mediated conditions, translational cellular therapies, and T cell engineering. She has contributed to significant advancements in the understanding and treatment of hematopoietic malignancies and solid organ transplant immunology.

Recent Grants

Grant: Close

Swammerdamprijs

Open Date: 2011-01-01

Close Date:

Mirjam H.M. Heemskerk

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (17)

Imaging mass cytometry reveals the order of events in the pathogenesis of immune-mediated aplastic anemia

Advancing the Integration of ‘Basic/Fundamental’ and Translational Cellular and Gene Therapy Science within the EBMT: Accelerating the Pathway to Progress

CAR-mediated target recognition limits TCR-mediated target recognition of TCR- and CAR-dual-receptor-edited T cells

TCR targeting hematopoiesis to cure leukemia

Balanced Epigenetic Regulation of MHC Class I Expression in Tumor Cells by the Histone Ubiquitin Modifiers BAP1 and PCGF1

DNA barcoded peptide-MHC multimers to measure and monitor minor histocompatibility antigen-specific T cells after allogeneic stem cell transplantation

Chimeric HLA antibody receptor T cells to target HLA‐specific B cells in solid organ transplantation

Combining BCMA-targeting CAR-T with TCR-engineered T-cell therapy to prevent immune escape of multiple myeloma

Inhibition of SUMOylation enhances DNA hypomethylating drug efficacy to reduce outgrowth of hematopoietic malignancies

SARS‐CoV‐2 mRNA vaccination of aplastic anemia patients is safe and effective

Human CD34+-derived complete plasmacytoid and conventional dendritic cell vaccine effectively induces antigen-specific CD8+ T cell and NK cell responses in vitro and in vivo

Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure

T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion

An HLA-A*11:01-Binding Neoantigen from Mutated NPM1 as Target for TCR Gene Therapy in AML

Clinically applicable CD34+-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses

Peptide Binding to HLA-E Molecules in Humans, Nonhuman Primates, and Mice Reveals Unique Binding Peptides but Remarkably Conserved Anchor Residues

Immunopeptidome Analysis of HLA-DPB1 Allelic Variants Reveals New Functional Hierarchies

Collaborators (18)

Marieke Griffioen

Jacques Neefjes

Tassilo Leo Alexander Wachsmann

Tom H. M. Ottenhoff

Claire Booth

Jan Wouter Drijfhout

Jennifer Tjon

Emanuele Angelucci

Alfred Vertegaal

Sebastiaan Heidt

Jannie Borst

Yanling Xiao

Ferenc Scheeren

Jeanette Leusen

Marieke Ijsselsteijn

Simona Pagliuca

Jurgen Kuball

Hendrik Veelken

How do I reach out?

Meet Kite AI